Wolfgang W. Wolfgang Fleischhacker
#198,957
Most Influential Person Across History
Wolfgang W. Wolfgang Fleischhacker's AcademicInfluence.com Rankings
Download Badge
Biology
Wolfgang W. Wolfgang Fleischhacker's Degrees
- Doctorate Medicine University of Vienna
- PhD Psychiatry University of Vienna
Why Is Wolfgang W. Wolfgang Fleischhacker Influential?
(Suggest an Edit or Addition)Wolfgang W. Wolfgang Fleischhacker's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial (2008) (1040)
- Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. (2008) (322)
- Guidelines for depot antipsychotic treatment in schizophrenia (1998) (312)
- Comparison of acamprosate and placebo in long-term treatment of alcohol dependence (1996) (311)
- Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. (2003) (302)
- Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). (2009) (282)
- World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia (2008) (277)
- Compliance with antipsychotic drug treatment: influence of side effects. (1994) (260)
- Metabolic side effects of antipsychotic medication (2007) (255)
- Quality of life in breast cancer patients--not enough attention for long-term survivors? (2001) (248)
- Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial (2017) (209)
- Sex differences in cognitive functions (2003) (206)
- Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. (2012) (187)
- Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. (2012) (181)
- Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. (2010) (177)
- Association of olanzapine-induced weight gain with an increase in body fat. (2001) (176)
- The clinical implications of weight gain in schizophrenia. (2001) (173)
- Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. (2004) (170)
- Gender differences in regional cerebral activity during the perception of emotion: A functional MRI study (2006) (161)
- The impact of hemoglobin levels on fatigue and quality of life in cancer patients. (2002) (159)
- Stratified medicine for mental disorders (2014) (159)
- Compliance with antipsychotic treatment (2000) (154)
- Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. (2014) (152)
- Akathisia: an updated review focusing on second-generation antipsychotics. (2009) (148)
- Factors influencing compliance in schizophrenia patients. (2003) (148)
- Schizophrenia--time to commit to policy change. (2014) (146)
- Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice (2009) (145)
- A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. (1992) (142)
- Influence of patient-related variables on clozapine plasma levels. (1990) (139)
- Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study (2014) (135)
- Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial (2013) (134)
- The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. (2017) (132)
- Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. (2004) (131)
- Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. (2016) (129)
- Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study (2016) (127)
- The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics (1998) (126)
- Weight gain induced by clozapine (1995) (124)
- Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors (2004) (121)
- Managing Antipsychotic-Induced Acute and Chronic Akathisia (2000) (118)
- Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. (2018) (118)
- Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. (1994) (116)
- Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. (1992) (114)
- Use of alternative / complementary therapy in breast cancer patients – a psychological perspective (2001) (113)
- Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study (2009) (113)
- Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. (1999) (109)
- Selection bias in clinical trials with antipsychotics. (2000) (107)
- Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST) (2009) (107)
- Sexual Dysfunction in First-Episode Schizophrenia Patients: Results From European First Episode Schizophrenia Trial (2011) (105)
- Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. (2019) (102)
- A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. (2012) (102)
- Language lateralization in unmedicated patients during an acute episode of schizophrenia: A functional MRI study (2006) (98)
- The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial (2005) (97)
- Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. (2007) (97)
- Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. (2002) (94)
- Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age (2004) (92)
- Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. (1990) (91)
- Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment (2005) (88)
- Brain activation patterns during a selective attention test — a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia (2007) (88)
- Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study (2013) (87)
- Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder (2006) (86)
- The promise of biological markers for treatment response in first-episode psychosis: a systematic review. (2015) (85)
- Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis (2013) (84)
- Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. (2005) (83)
- Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies (2017) (83)
- No evidence for an association between serum cholesterol and the course of depression and suicidality (2004) (83)
- Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double‐blind trial vs. haloperidol (1992) (83)
- Effect of cannabis use on cognitive functions and driving ability. (1999) (82)
- Clozapine-induced transient white blood count disorders. (1994) (81)
- Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells (2005) (81)
- Assessment of the alcohol withdrawal syndrome--validity and reliability of the translated and modified Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-A). (1994) (79)
- Brain activation patterns during a selective attention test—a functional MRI study in healthy volunteers and patients with schizophrenia (2003) (74)
- Hepatotoxicity of clozapine. (1997) (74)
- Quality of life measurement in oncology--a matter of the assessment instrument? (2001) (74)
- Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. (2013) (74)
- Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial (2016) (73)
- Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. (2016) (73)
- Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients (2005) (72)
- The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia (2002) (72)
- Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? (2012) (70)
- Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. (2004) (69)
- Hippocampal volume reduction in male schizophrenic patients (1998) (68)
- Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. (1992) (67)
- EEG alterations in patients treated with clozapine in relation to plasma levels (1992) (66)
- An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. (2003) (66)
- Second-generation antipsychotic long-acting injections: Systematic review (2009) (65)
- Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study (2016) (64)
- Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective (2013) (64)
- Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. (1994) (62)
- The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors (2019) (60)
- Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF) (1998) (60)
- Time after bone marrow transplantation as an important variable for quality of life: results of a cross-sectional investigation using two different instruments for quality-of-life assessment (1998) (59)
- Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study (2013) (59)
- Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. (2009) (58)
- Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. (1989) (57)
- Symptomatic remission and neurocognitive functioning in patients with schizophrenia (2011) (57)
- Antipsychotic Drug Treatment in First-Episode Psychosis: Should Patients be Switched to a Different Antipsychotic Drug After 2, 4, or 6 Weeks of Nonresponse? (2010) (56)
- Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia (1995) (56)
- New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. (2014) (56)
- Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). (2011) (54)
- Extrapyramidal side effects of clozapine and haloperidol (1995) (50)
- Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (48)
- Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period (2005) (48)
- Placebo or active control trials of antipsychotic drugs? (2003) (48)
- Psychotic disorders in DSM-5 and ICD-11 (2016) (46)
- The usefulness and use of second-generation antipsychotic medications: Review of evidence and recommendations by a Task Force of the World Psychiatric Association. (2002) (45)
- Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. (2003) (45)
- A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale (2019) (45)
- Hepatotoxicity of clozapine (1996) (44)
- CSF of neuroleptic-naive first-episode schizophrenic patients: Levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin) (1996) (42)
- Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. (2014) (42)
- Neutropenia induced by second generation antipsychotics: a prospective investigation. (2007) (41)
- Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View (1991) (41)
- Effects of clozapine on hematopoiesis and the cytokine system (1993) (41)
- Adverse effects of antipsychotic drugs (1995) (38)
- Risk factors for the development of neuroleptic induced akathisia (1997) (38)
- Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia (2013) (37)
- Long-term pharmacokinetics of clozapine (1998) (36)
- Clozapine: a comparison with other novel antipsychotics. (1999) (36)
- Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. (2010) (35)
- Off-label use of antipsychotic drugs (1998) (34)
- Benzodiazepines and Other Psychotropic Drugs Abused by Patients in a Methadone Maintenance Program: Familiarity and Preference (1992) (34)
- The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. (2015) (34)
- Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. (2015) (33)
- Neural substrates for episodic encoding and recognition of unfamiliar faces (2007) (33)
- Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
- Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies (2019) (32)
- Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection. (1988) (31)
- The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: Case reports (1992) (31)
- Cognitive impairment in schizophrenia: Clinical ratings are not a suitable alternative to neuropsychological testing (2007) (30)
- Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST (2014) (30)
- Schizophrenia: when clozapine fails (2015) (29)
- Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. (1997) (29)
- Dose-related plasma levels of clozapine. (1989) (28)
- Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients (1999) (28)
- Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST) (2015) (28)
- Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. (2000) (28)
- Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST) (2016) (27)
- Negative symptoms in schizophrenia: considerations for clinical trials (1994) (27)
- Is schizophrenia linked to alteration in cellular immunity? (1989) (26)
- Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective (2011) (26)
- Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. (2018) (26)
- New developments in the pharmacotherapy of schizophrenia. (2003) (26)
- Carbamazepine in the prophylaxis of mood disorders. (1990) (26)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. (1992) (25)
- Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia (2009) (24)
- Off-label use of antipsychotic drugs. (2000) (24)
- Transient neutropenia induced by clozapine. (1992) (24)
- Does eosinophilia predict clozapine induced neutropenia? (1996) (23)
- Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). (2023) (23)
- The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. (2016) (23)
- Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study. (2018) (23)
- Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials (2013) (23)
- Self-stigma versus stigma resistance in schizophrenia: Associations with resilience, premorbid adjustment, and clinical symptoms (2019) (23)
- Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. (2003) (23)
- Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. (2007) (22)
- Compliance and Outcome in Patients Treated with Antipsychotics (1996) (22)
- P0117 - Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study (2008) (22)
- The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study (2005) (22)
- The WPA global programme against stigma and discrimination because of schizophrenia (1998) (22)
- Psychiatric Disorder (2020) (22)
- Switching Between Second-Generation Antipsychotics (2005) (22)
- Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross‐sectional study (2018) (22)
- Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus? (1994) (21)
- Intravenous versus oral administration of amitriptyline in patients with major depression. (2000) (21)
- Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies (2014) (21)
- Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis (2007) (21)
- Mood-altering effects of biperiden in healthy volunteers. (1987) (20)
- Risk profile of SSrIs in elderly depressive patients with co-morbid physical illness. (2001) (20)
- Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. (1994) (20)
- The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. (2003) (20)
- Propanolol for fluoxetine-induced akathisia (1991) (19)
- The effects of alcohol and benzodiazepines on the severity of ski accidents (1992) (19)
- Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder (2016) (19)
- Further Evidence that Behavioral Tests and Neuropeptide mRNA and Tissue Level Alterations Can Differentiate between Typical and Atypical Antipsychotic Drugs (2000) (19)
- Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other (2006) (19)
- Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe (2002) (19)
- Affective prosody perception in symptomatically remitted patients with schizophrenia and bipolar disorder (2014) (18)
- The neural regions sustaining episodic encoding and recognition of objects (2007) (18)
- Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies (2016) (18)
- Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy (1993) (18)
- Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment (2001) (17)
- Antipsychotics in the early stage of development (2009) (17)
- Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. (2013) (17)
- Propranolol treatment of olanzapine-induced akathisia. (1997) (17)
- Bilirubin concentration correlates with positive symptoms in patients with schizophrenia. (2016) (17)
- Are patterns of benzodiazepine use predictable? (1993) (17)
- 756 The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics (1997) (17)
- Paliperidone: a review of clinical trial data and clinical implications. (2012) (17)
- Carbamazepine Monotherapy in the Treatment of Alcohol Withdrawal (1990) (16)
- The interrelation of needs and quality of life in first-episode schizophrenia (2012) (16)
- Efficacy of medium-dose clozapine for treatment-resistant schizophrenia. (1995) (16)
- A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. (2001) (16)
- A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. (1995) (15)
- The role of carbamazepine in the prophylaxis of unipolar depression. (1993) (15)
- Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia (2014) (15)
- Intravenous flunitrazepam in the treatment of alcohol withdrawal delirium. (1993) (15)
- Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment (2011) (15)
- Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study (2018) (15)
- Do phase III trials have clinical value? (1999) (15)
- Transient increase of liver enzymes induced by risperidone: two case reports. (1999) (14)
- Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? (2013) (14)
- The psychopharmacology of schizophrenia (1999) (14)
- Combined Clozapine and Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia: Clinical and Cognitive Outcomes (2011) (14)
- How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses (2014) (13)
- Abuse potential of carbamazepine. (1993) (13)
- Drug Treatment of Schizophrenia in the 1990s (1997) (13)
- Eff ectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder : an open randomised clinical trial (2008) (13)
- Emerging drugs for schizophrenia (2011) (12)
- Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. (2015) (12)
- Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series. (2007) (12)
- [Neurocognition and social cognition in patients with schizophrenia or mood disorders]. (2010) (11)
- Executive Dysfunctions Predict Self-Restricted Driving Habits in Elderly People with or without Alzheimer’s Dementia (2017) (11)
- Akathisia induced by necrosis of the basal ganglia after carbon monoxide intoxication (1995) (11)
- Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study (2014) (11)
- Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. (2005) (11)
- Attitudes of patients with schizophrenia and depression towards psychiatric research (2010) (11)
- The Hillside Akathisia Scale: a reliability comparison of the English and German versions (2006) (11)
- Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. (2013) (11)
- Acute effects of exercise on affective responses, cravings and heart rate variability in inpatients with alcohol use disorder – A randomized cross-over trial (2017) (10)
- Introduction: Weight Gain: A Growing Problem in Schizophrenia Management (2001) (10)
- Aripiprazole (2005) (10)
- ICI 204636 (‘Seroquel’)—A putative new atypical antipsychotic: Results from phase III trials (1996) (10)
- Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. (2009) (10)
- ‘Atypical antipsychotics’ and the semantics of psychopharmacology (2002) (10)
- Fluperlapine vs haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids. (1986) (9)
- Results of an open phase II study with zotepine--a new neuroleptic compound. (1987) (9)
- Pioneering ideas for the physical and chemical sciences : Josef Loschmidt's contributions and modern developments in structural organic chemistry, atomistics, and statistical mechanics : proceedings of the Joseph Loschmidt Symposium, held June 25-27, 1995, in Vienna, Austria (1997) (9)
- PERCEPTION OF AFFECTIVE PROSODY IN REMITTED PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER I (2010) (9)
- Improvement of cognitive dysfunction after treatment with second-generation antipsychotics. (2002) (9)
- EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME (2014) (9)
- Experimental antipsychotics and metabolic adverse effects--findings from clinical trials. (2009) (9)
- Corrigendum to “Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial” [Schizophr. Res. 176 (2016) 264–271] (2017) (8)
- [Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study]. (1991) (8)
- Characteristics of benzodiazepine long-term users: investigation of benzodiazepine consumers among pharmacy customers (2005) (8)
- How precise is precision medicine for schizophrenia? (2016) (8)
- Optimising Prophylactic Treatment of Schizophrenia by Means of Treatment Standards and Compliance Improvement (1992) (8)
- Why do indiviuals with schizophrenia drop out of observational clinical trials? (2017) (8)
- Piracetam in alcoholic organic mental disorder: a placebo controlled study comparing two dosages. (1986) (8)
- Adherence to Antipsychotics in Schizophrenia (2013) (8)
- Naming for Psychotropic Drugs: Dilemma and Challenge (2017) (8)
- A Meta View on Meta-analyses. (2017) (7)
- Weight gain induced by olanzapine (1998) (7)
- Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use (2003) (7)
- EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS IN FIRST-EPISODE SCHIZOPHRENIA AND SCHIZOPHRENIFORMDISORDER (2008) (7)
- Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia. (2004) (7)
- Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs (2018) (7)
- P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial (2015) (7)
- Management of behavioural emergencies (1991) (6)
- Second generation antipsychotics (2002) (6)
- Management of a risperidone-induced tardive Pisa syndrome: a case report. (2012) (6)
- [Psychiatric consultation service. An analysis of demand and utilization in the Innsbruck general public district hospital (university clinics)]. (1986) (6)
- Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study (2012) (6)
- The first-episode of schizophrenia: a challenge for treatment (2002) (6)
- Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia (2016) (6)
- Hyponatremia-induced organic mental disorder may mask paranoid schizophrenia (1987) (6)
- Ritanserin in the treatment of neuroleptic-induced akathesia (1990) (6)
- Antipsychotic medications for schizophrenia. (2014) (6)
- Change in HIV-antibody seroprevalence rates in i.v. drug dependent prisoners. (1991) (6)
- Tolerability of antipsychotics: recent controversies and future management. (2009) (6)
- Adverse effects and antipsychotic long-acting injections (2010) (6)
- Dose-related plasma levels of clozapine: influence of smoking, sex. and age (1989) (6)
- Managing the prodrome of schizophrenia. (2012) (5)
- P.3.c.076 Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine (2008) (5)
- Interpreting treatment trials in schizophrenia patients: Lessons learned from EUFEST (2012) (5)
- Usefulness of screening EEGs in psychiatric inpatients. (1992) (5)
- Benzodiazepines: utilization and patterns of use in a university hospital. (1989) (5)
- The long‐term treatment of schizophrenia with antipsychotics: a perennial debate (2018) (5)
- Delirium following benzodiazepine withdrawal. (1987) (4)
- Investigation of benzodiazepine-consumers concerning intake-habits, signs of abuse or dependence, and information about the drug. (1988) (4)
- Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs. (2018) (4)
- Transient hyperproinsulinemia during treatment with clozapine and amisulpride. (2004) (4)
- Termination of clozapine treatment (1996) (4)
- Treatment of negative symptoms in schizophrenia with zotepine. (1987) (4)
- [Neuroleptic-induced akathisia]. (1989) (4)
- Low-dose zotepine in the maintenance treatment of schizophrenia. (1987) (4)
- Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics: A Naturalistic Follow-Up Study (2016) (4)
- Differential effects of phencyclidine application on secretogranin II expression in organotypic slices of rat prefrontal cortex (2003) (4)
- Immunologic Alterations in Schizophrenia: Neopterin, L-Kynurenine, Tryptophan and T-Cell Subsets in the Acute Stage of Illness (2002) (4)
- High versus low-dose piracetam in alcohol organic mental disorder: a placebo controlled study (2005) (4)
- Treatment of alcohol organic mental disorder with piracetam (1987) (4)
- [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol]. (1991) (4)
- Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study (2019) (3)
- Vulnerable phases in adolescence represented by means of committed suicide. (1991) (3)
- Nootropics (1993) (3)
- Are all antipsychotics equal? – Authors' reply (2008) (3)
- Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period (2018) (3)
- P.3.c.018 A placebo-controlled study of efficacy/safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia (2012) (3)
- Personality: Neurobehavioural Foundation and Pharmacological Protocols (2014) (3)
- T-cell subsets in schizophrenic patients (1992) (3)
- Common Variants near the Melanocortin 4 Receptor Gene are Associated with Severe Antipsychotic Drug-induced Weight Gain (2014) (3)
- M128. Quality of Life in Patients With Schizophrenia: Its Associations With Resilience, Self-Esteem, Hopelessness, and Psychopathology (2017) (3)
- Comprar Adherence To Antipsychotics In Schizophrenia | Sacchetti, E. | 9788847026780 | Springer (2013) (2)
- Extrapyramidal side effects of clozapine (1992) (2)
- Methodological challenges in the clinical development of antipsychotic drugs (2000) (2)
- 586 Selection bias in clinical trials with antipsychotics (1997) (2)
- SIBUTRAMINE IN THE TREATMENT OF ANTIPSYCHOTIC-INDUCES WEIGHT GAIN: A RANDOMIZED, PLACEBO-CONTROLLED DOUBLE-BLIND STUDY (2010) (2)
- Psychoneuroimmunology : hypotheses and current research (2001) (2)
- Osteoporosis in young patients with schizophrenia (2002) (2)
- Placebo-controlled clinical trials: Patients' attitudes (2000) (2)
- [Benzodiazepine prescriptions at a university clinic]. (1987) (2)
- P.3.c.019 Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia (2012) (2)
- Neopterin and biopterin CSF levels in tardive dyskinesia after clozapine treatment (1993) (2)
- Nicotine Dependence and Its Treatment (2010) (2)
- Second-generation antipsychotics: are their similarities greater than their differences? (2003) (2)
- P.2.061 Long-acting risperidone injection improves and maintains quality of life in patients with schizophrenia (2003) (2)
- P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole (2013) (2)
- Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia (2013) (2)
- Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study (2021) (2)
- 2277 – A Placebo-controlled Study Of Efficacy And Safety Of Aripiprazole Once-monthly For Long-term Maintenance Treatment In Schizophrenia (2013) (2)
- Should a 'psychosis risk syndrome' be a separate diagnosis in DSM-5? (2012) (2)
- 31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS (2018) (2)
- Academic Highlights: New Developments in Antipsychotic Therapy. [CME] (1899) (2)
- Schizophrenia and substance abuse: Is schizophrenia forgotten? (2017) (2)
- Clozapine - Beneficial and Untoward Effects: An Update (1992) (2)
- Psychoneuroimmunology: Hypotheses and Current Research 6th Expert Meeting on Psychoimmunology, Innsbruck, January 2000 (2001) (1)
- Poster #S10 POLYPHARMACY TO COUNTERACT ANTIPSYCHOTIC-INDUCED WEIGHT GAIN AND METABOLIC ADVERSE EFFECTS IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS (2014) (1)
- Encouraging a new generation of researchers in a time of limited resources. (2013) (1)
- Excitatory Amino Acids and Their Antagonists (2015) (1)
- P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole (2013) (1)
- P.3.d.079 Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study (2015) (1)
- The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations (2022) (1)
- EPA-0790 – All-cause Discontinuation and Safety of Aripiprazole Once-Monthly for the Treatment of Schizophrenia: A Pooled Analysis of two Double-Blind, Randomized, Controlled Trials (2014) (1)
- Characteristics of Involuntarily Admitted Patients and Treatment Patterns Over a 21-Year Observation Period (2018) (1)
- The problem of substance abuse in people with schizophrenia. (2015) (1)
- Influence of milk on haloperidol pharmacokinetics. (1994) (1)
- Water intoxication in the course of an acute schizophrenic episode (2004) (1)
- Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes. (2010) (1)
- Weight gain induced by clozapine and haloperidol (1993) (1)
- P.3.d.033 Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia (2016) (1)
- Reply to "Psychotic Symptoms Associated With Topiramate: Cognitive Side Effects or Worsening of Psychosis"? (2004) (1)
- Schizophrenia treatment: entering a new decade. (2010) (1)
- Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models (2022) (1)
- Changes in psychopharmacological treatment strategies in schizophrenia—iIpatient treatment 1989 vs. 1995 (1998) (1)
- Poster #S233 ALL-CAUSE DISCONTINUATION AND SAFETY OF ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA: A POOLED ANALYSIS OF TWO DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIALS (2014) (1)
- Maintenance treatment in schizophrenia: Current status in Austria (1990) (1)
- Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
- [Compliance problems in treatment of schizophrenic patients]. (1998) (1)
- Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial (2012) (1)
- Clozapine in the treatment of first- and multiple-episode patients with schizophrenia (2000) (1)
- PS04.01 Pharmacological treatment of schizophrenia (2000) (1)
- P-3-4 Acamprosate in the relapse prevention of alcohol dependence (1996) (1)
- S-42-6 Placebo-induced side effects in clinical trials with schizophrenic patients (1996) (1)
- Variables influencing outpatients compliance (1998) (1)
- Osteoporosis in patients suffering from schizophrenia (2003) (1)
- Decreased substance P- and increased calcitonin gene-related peptide immunoreactivities in the cerebrospinal fluid of drug-naive schizophrenic patients (1991) (1)
- Are original, branded psychotropics and generic medications interchangeable? (2013) (1)
- Has there been progress in schizophrenia research and treatment for all peoples during 2008? Existing disparities in mental healthcare and research? (2009) (1)
- Attitudes towards illness, antipsychotic medication and compliance in outpatients with schizophrenia (1999) (1)
- Substance abuse terminology. (1988) (1)
- Conflicting views on conflicts of interest in medicine. (2007) (1)
- Sexual Dysfunction in First-Episode Schizophrenia Patients : Results from EUFEST (2016) (0)
- P.6.033 Effects of cannabis use on cognitive functions and driving ability (1997) (0)
- Incidence of neuroleptic-induced akathisia (1992) (0)
- MRI volumetric follow-up study of schizophrenic patients (1998) (0)
- P-4-21 Sexual dysfunctions induced by typical and atypical antipsychotics (1995) (0)
- CAN THE ONGOING USE OF PLACEBO IN RELAPSE-PREVENTION CLINICAL TRIALS IN SCHIZOPHRENIA BE JUSTIFIED? (2014) (0)
- P-2-22 Amitriptyline and nortriptyline: Are plasma levels after first dose predictive for therapeutical efficacy? (1996) (0)
- RISK/BENEFIT ANALYSIS IN RELAPSE PREVENTION OF SCHIZOPHRENIC PSYCHOSIS (1992) (0)
- [Extrapyramidal side-effects: avoidance, diagnosis and treatment]. (2005) (0)
- Need for and problems with placebo-controlled studies (2001) (0)
- Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial (2022) (0)
- W01.03 Why is it important for Austria to establish an anti-stigma-programme on schizophrenia? (2000) (0)
- Riluzole intoxication in a patient with Huntington's disease — a neuropsychological case report (2000) (0)
- 519. Efficacy and Safety of Paliperidone Palmitate (3-Month versus 1-Month formulation) in European and Non-European Patients with Schizophrenia (2017) (0)
- What is an animal model ? (2005) (0)
- Survey and Follow-up of Patients Admitted to Innsbruck University Hospital for Attempted Suicide in 1983 (1988) (0)
- Stratification and prediction of remission in first-episode psychosis patients OPTIMISE (2019) (0)
- C.14.03 Designing and implementing global CNS development programs: disease-specific considerations (2009) (0)
- Acknowledgement to assessors (2010) (0)
- Second generation antipsychotics reduce dropout rates compared with first generation antipsychotics (2010) (0)
- Large pragmatic long term clinical trials in schizophrenia (2007) (0)
- M81 SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS (2019) (0)
- Seasonal bulimia treated with fluoxetine and phototherapy. (1993) (0)
- S242. INTERNALIZED STIGMA AND ITS ASSOCIATION WITH CLINICAL SYMPTOMS AND PREMORBID ADJUSTMENT IN STABLE SCHIZOPHRENIA (2018) (0)
- SAT5-Satellite symposium: DOPAMINE TRANSPORTER SPECT IN THE DIFFERENTIAL DIAGNOSIS OF DEMENTIA-A NEW CLINICAL TOOL Sponsored by GE Healthcare (2007) (0)
- Plasma levels of amitriptyline after a single dose - a predictor for treatment response? (1992) (0)
- DE03.01 Should-second Generation Antipsychotics be Favored Over Traditional Neuroleptics in the Treatment of Patients With Schizophrenia? (2000) (0)
- FACIAL AFFECT RECOGNITION IN REMITTED PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER I (2010) (0)
- The influence of clozapine on the cytokine system (1993) (0)
- NEUROCOGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS: IS THERE A DIFFERENCE BETWEEN REMITTED AND NON-REMITTED PATIENTS? (2010) (0)
- Poster #198 DIFFERENTIAL DIAGNOSIS AND TREATMENT OF DEPRESSIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA (2012) (0)
- Preliminary Pages / Contents / Preface (2001) (0)
- [Pharmacotherapy for schizophrenia]. (2006) (0)
- Experimental Psychopathology in Biological Psychiatry and Psychopharmacology (1992) (0)
- Differential alterations in enkephalin mRNA expression in rat brain after chronic treatment with zotepine, clozapins and haloperidol (1998) (0)
- Electrical conductor with a solder deposit on a contact portion (2003) (0)
- Quality of life and drug attitude in schizophrenia outpatients (2000) (0)
- P.2.051 Weight gain induced by clozapine (1997) (0)
- Premorbid social functioning and depressive symptoms predict internalized stigma in stable schizophrenia (2018) (0)
- The incidence of neuroleptic-induced akathisia (1992) (0)
- SU117. Peripheral Cytokines After 3 Weeks of Antipsychotic Treatment (2017) (0)
- The effect of novel antipsychotic drug treatment on cognitive stimulation using the stroop test in patients with schizophrenia — A functional MRI study (2000) (0)
- Utilisation of benzodiazepines in a university hospital. (1988) (0)
- PLACEBO CONTROLLED TRIALS IN PATIENTS SUFFERING FROM SCHIZOPHRENIA: METHODOLOGICAL ISSUES WITH AN INDIRECT EFFECT ON ETHICAL CONSIDERATIONS (2014) (0)
- P.3.d.048 Expected and effective plasma concentrations of antipsychotics and changes in psychopathology (2013) (0)
- Alterations of glucose metabolism under treatment with atypical antipsychotics (2004) (0)
- JW01.03 - Lessons from schizophrenia study: Eufest (2008) (0)
- ALTERATIONS OF GLUCOSE METABOLISM IN PATIENTS TREATED WITH ZIPRASIDONE VS. CLOZAPINE (2010) (0)
- SU129. Transcultural Comparison of the Impact of Symptomatic Remission and Resilience on Health-Related Quality of Life in Patients Suffering From Serious Mental Illness. (2017) (0)
- S.14.05 Metabolic side effects of antipsychotics (2006) (0)
- Differential regulation of chromogranin peptides by PCP (2001) (0)
- An MRI volumetric study in schizophrenic patients (1996) (0)
- Poster #249 COMPLIANCE IN SCHIZOPHRENIA PATIENTS: THE ROLE OF THERAPEUTIC ALLIANCE – INTRODUCTION OF A NEW RATING INSTRUMENT (2012) (0)
- Kinetics of oral clozapine (1990) (0)
- Weight gain: a frequent side-effect of clozapine treatment (1992) (0)
- Alcohol and benzodiazepines — Risk factors in accidents (2001) (0)
- Safety, tolerability and compliance in the use of antipsychotics (2002) (0)
- P.3.d.049 Expected and effective plasma concentrations of antipsychotic drugs and attitude toward treatment (2013) (0)
- P.3.c.034 Eufest: the moderating impact of metabolic co-morbidities on treatment outcomes in first-episode schizophrenia (2009) (0)
- Influence of patient-related variables on plasma levels of clozapine (1989) (0)
- Extrapyramidal side-effects and prediction of neuroleptic treatment response (1994) (0)
- Alterations of glucose metabolism during treatment with clozapine versus amisulpride (2003) (0)
- The incidence of neuroleptic induced akathisia (1993) (0)
- C.04.05 Symptomatic control should be prioritised in the treatment of schizophrenia (2016) (0)
- Successful Electroconvulsive Therapy in a Clozapine-Refractory Schizophrenia Patient with Meningioma. (2017) (0)
- NREM Sleep (0)
- To: Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215–221 (2005) (0)
- SS-08. Section symposium: Schizophrenia —Nature and narratives (2005) (0)
- Benign neutropenia induced by clozapine (1992) (0)
- ABSTRACTS SCANDINAVIAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY SCNP 56th Annual Meeting, April 22th – 24th, 2015 Copenhagen, Denmark (2015) (0)
- P.2.031 Selection bias in clinical trials with antipsychotics (1997) (0)
- S-9-5 Contemporary and anticipated approaches to the reduction of antipsychotic induced side effects (1996) (0)
- C.02.02 Options for addressing the side effects of atypical antipsychotics (2008) (0)
- The neural correlates of episodic encoding and recognition of words in unmedicated patients with acute episode of schizophrenia: A functional MRI study (2003) (0)
- MRI-measurements in schizophrenics (1995) (0)
- The valid assessment and diagnosis of akathisia is of great importance for antipsychotic treatment and for the evaluation of the side-effects of neuroleptics (2006) (0)
- P.3.f.012 Association between bilirubin and schizophrenia: a longitudinal study (2013) (0)
- Classical antipsychotics in the treatment of negative symptoms (1993) (0)
- Speaker 2: Jeff Lieberman, USA (2016) (0)
- ATTITUDES TOWARD A SPECIALIZED OUTPATIENT SERVICE IN PATIENTS WITH SCHIZOPHRENIA (2008) (0)
- Poster #220 MANAGEMENT OF INVOLUNTARILY ADMITTED PATIENTS WITH SCHIZOPHRENIA (2012) (0)
- The impact of side effects — Patient, family and physician concerns (1998) (0)
- Clozapine induced neutropenia as an effect of decreased cytokine release (1992) (0)
- Activation tasks in neuroleptic-induced akathisia (1991) (0)
- Pharmacogenetics of Antipsychotic-Induced Weight Gain in Multiple Medication-Naive Cohorts (2017) (0)
- Clozapine in the treatment of first and multi-episode schizophrenic patients (1995) (0)
- SS-09. Section symposium: Antipsychotics:Effectiveness beyond mere symptom control in schizophrenia patients (2005) (0)
- Supplement to the list of reviewers that collaborated in 2001: (2002) (0)
- [Problems in evaluating new antipsychotic drugs]. (1998) (0)
- Is clozapine induced neutropenia caused by a decreased cytokine release? (1992) (0)
- Hematologic side effects of clozapine (1992) (0)
- Future Perspectives in Antipsychotic Drug Development (2000) (0)
- Predictors for longterm use of benzodiazepines (1992) (0)
- Speaker 3: Wolfgang Fleischhacker, Austria (2016) (0)
- Paliperidone Palmitate 3-month versus 1-month formulation in patients with Schizophrenia: a randomized, double-blind, noninferiority study (2016) (0)
- The preference of psychotropic drugs abused by patients in a methadone maintenance program (1991) (0)
- Schizophrenia: Patients' attitudes toward their illness in comparison to other diseases and the issue of compliance (2000) (0)
- S32.03 New antipsychotics: The issue of side-effects (2000) (0)
- USEFULNESS OF SCREENING EEGS IN PSYCHIATRIC INPATIENTS. AUTHOR'S REPLY (1992) (0)
- Are schizophrenia and antipsychotic treatment risk factors for osteoporosis? (2001) (0)
- Second generation antipsychotics. (2002) (0)
- New topics and controversies in schizophrenia research (2006) (0)
- [Steroid-induced psychoses]. (1995) (0)
- Coprescription of antipsychotics and antidepressants: Why, when and how? (2000) (0)
- C.03.02 Long-term management: how can long-acting injectables benefit patients with schizophrenia? (2012) (0)
- Atypical antipsychotics. Edited by Ellenbroek and Cools. Birkhauser, 2000. Pages: 236 + xi. ISBN: 3-7643-5948-X. Price: 75.00. (2001) (0)
- Muscarinic Cholinergic Receptor Agonists and Antagonists (2015) (0)
- Polypharmacy: the good, the bad and the ugly. (2014) (0)
- Technology-driven science: will it advance treatment of schizophrenia going into the second decade of the 21st century? (2011) (0)
- Aripiprazole long-acting injection (2016) (0)
- Predictive Validity (2022) (0)
- 2281 – Psychosocial And Overall Effectiveness Of Aripiprazole Once-monthly Vs. Placebo Once-monthly For Maintenance Treatment In Schizophrenia (2013) (0)
- S-51. Symposium: Treatment of first episodeschizophrenia (2005) (0)
- Adverse Effects of Atypical Antipsychotics (1998) (0)
- SS-05. Section symposium: Genes forschizophrenia: Susceptibility to what? part II: Insights from neuroimaging (2005) (0)
- P.3.d.034 How do we treat involuntarily admitted patients with schizophrenia? (2013) (0)
- SA16. Why do Individuals With Schizophrenia Drop Out From Naturalistic Clinical TRIALS (2017) (0)
- Drug attitude during the initial treatment period: A prospective follow-up study in patients with schizophrenia (2007) (0)
- P-22-1 Patients selection in clinical trials with antipsychotics (1996) (0)
- COMBINED CLOZAPINE AND ELECTROCONVULSIVE THERAPY IN CLOZAPINE-RESISTANTSCHIZOPHRENIA: IMPACT ON CLINICAL AND COGNITIVE OUTCOME (2008) (0)
- The authors reply (2012) (0)
- AGE AND SEX DIFFERENCES IN INSIGHT IN A LARGE SAMPLE OF STABLE PATIENTS WITH SCHIZOPHRENIA (2008) (0)
- Old versus new antipsychotic drugs in relation to treatment concordance (2002) (0)
- Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. (2023) (0)
- Reply (2006) (0)
- Invited speaker—Neuropeptides in schizophrenic disorder and their regulation by antipsychotic agents (1993) (0)
- P.2.056 Effects of clozapine and haloperidol on hematopoiesis (1997) (0)
- P.5.025 Characteristics of patients with a prescription of benzodiazepine (1996) (0)
- [Effect of alcohol and benzodiazepines on the severity of ski accidents]. (1991) (0)
- C.17.04 Can we improve psychotic symptom control/ response in acute episodes of schizophrenia? (2007) (0)
- P.3.c.053 Relating reported extrapyramidal adverse events to movement disorder rating scales in ziprasidone randomised clinical trials (2011) (0)
- Concentrations of secretoneurin and chromogranin a immunoreactivities in the cerebrospinal fluid of schizophrenic patients (1995) (0)
- Invited comment (1999) (0)
- An international survey on information needs of patients with schizophrenia and their carers and management issues most frequently encountered by professional care team members (2000) (0)
- P.2.032 Clozapine in the treatment of first- and multiepisode schizophrenic patients (1997) (0)
- Clozapine : A comparison with other novel antipsychotics : Current concepts and future prospects (1999) (0)
- Do Antipsychotics Affect Insight in Psychosis Differentially? Data From the EUFEST Trial. (2015) (0)
- P.2.038 Changes in psychopharmacological treatment strategies in schizophrenia — inpatient treatment 1989 vs. 1995 (1997) (0)
- Poster #228 AFFECTIVE PROSODY PERCEPTION IN REMITTED PATIENTS WITH SCHIZOPHRENIA COMPARED TO HEALTHY CONTROLS (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wolfgang W. Wolfgang Fleischhacker?
Wolfgang W. Wolfgang Fleischhacker is affiliated with the following schools:
